LATEST NEWS
February 4, 2026: ‘Radiance Biopharma invited speaker at Global Family Office Investment Summit‘ – EINPresswire
More……
September 3, 2025: ‘Radiance Biopharma signs exclusive license For ‘First In Class’ c-Met/EGFR targeted Nano Antibody ADC‘ – GlobeNewswire
More……
September 2, 2025: ‘Boston biotech Radiance offers China firm $1B-plus for rights to next-gen ADC‘ – FIERCE Biotech
More……
Radiance Biopharma’s mission is to develop a pipeline of next generation Antibody Drug Conjugates (ADCs) for the treatment of cancer and other high unmet medical needs.
Radiance’s Board of Directors, Management and Advisors are industry veterans with experience in both large pharma and biotechnology startups and are committed to transforming the lives of patients with cancer.
RB-601 is a ‘First-in-Man’ Nano Antibody Drug Conjugate targeting tumors expressing c-MET and EGFR. Learn more
RB-203 is a proprietary monoclonal antibody recognizing membrane Hsp70 which is expressed on the majority of tumors, but not normal cells. Learn more